Exscientia

Exscientia plc is a pharma tech business that uses artificial intelligence to research, design and develop drugs. The firm provides an end-to-end AI and technology solution for target identification, drug candidate design, translational models, and patient selection. Moreover, the company focuses on small-molecule drug candidates. This platform helps with the development of candidate drug molecules as well as the delivery of medication therapy to patients through AI-guided assessment.

Exscientia's motivation is to find faster and smarter ways to discover new and better medications. It will enable people to live more healthy and more productive lives by actively applying AI to precision engineer medicines more quickly and efficiently. To address this challenge, it is reimagining drug discovery by combining cutting-edge AI techniques with experimental innovation to create a new set of drug discovery processes.

From its inception in 2012, the company has been at the forefront of the development of an entirely novel field known as pharma tech, which is at the intersection of sophisticated AI applications and complex drug discovery. It was the first business to automate drug design and the first to have an AI-designed molecule enter clinical trials. Being a full-stack AI drug discovery company, it focuses on AI design as well as precise data generation. Together, these improve the strength and integrity of integrated AI and machine learning systems.

Founded: 2012
Headquarters: Oxford, United Kingdom
Website: https://www.exscientia.ai/